Leerink Partners & Morgan Stanley
5 shared events · Importance 3 · Last updated Aug 05, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Leerink Partners: Leerink Partners served as joint book-running manager, benefiting from underwriting fees and strengthening its healthcare franchise.
Morgan Stanley: Morgan Stanley acted as joint book-running manager, earning underwriting fees and reinforcing its role in biotech IPOs.
Aug 05, 2026 · 15 articles
Business
Leerink Partners: Leerink Partners is acting as a joint book-running manager for Trevi Therapeutics' public offering.
Morgan Stanley: Morgan Stanley is acting as a joint book-running manager for Trevi Therapeutics' public offering.
Apr 16, 2026 · 7 articles
Business
Leerink Partners: Investment bank; previously commented on Palsonify's approval.
Morgan Stanley: Provided $4.5B bridge financing to Vertex for the acquisition.
Jul 06, 2026 · 34 articles
Business
Leerink Partners: Leerink Partners has a neutral rating and a $131 price target, citing regulatory and technology uncertainties.
Morgan Stanley: Morgan Stanley reiterated a $300 price target on SpaceX, showing bullish sentiment despite the stock's decline.
Jun 18, 2026 · 319 articles
Business
Leerink Partners: Leerink Partners is a research firm whose analyst, Craig Moffett, offered a measured reception to the Siri AI updates.
Morgan Stanley: Morgan Stanley provided analysis on Apple Inc.'s Siri AI, noting that a significant portion of older iPhones will not support the advanced AI features due to hardware limitations.
May 19, 2026 · 254 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Leerink Partners and Morgan Stanley interact across events, view sentiment trends, and discover connected entities.
Open Dashboard